来源：陆道培医疗集团
第 52 届欧洲血液与骨髓移植学会（EBMT）年会将于 2026 年 3 月 22 日-25 日在西班牙马德里举行。作为全球造血干细胞移植与细胞治疗领域最具影响力的国际学术盛会之一，本届大会汇聚来自全球 90 余个国家和地区、超过 6000 名专家学者，围绕基础研究、临床转化、移植策略优化及细胞治疗创新等前沿议题展开深入交流。
本届年会，陆道培医学团队再度以亮眼成绩登上国际学术舞台，27 项研究成果成功入选，其中包括 2 项口头报告（Oral）、25 项墙报（18 篇 Poster/ 7 篇 ePoster），入选总数创下团队历年参加 EBMT 年会的新高。值得一提的是，陆道培医学团队在 EBMT 年会的入选成果数量已连续多年稳步增长。自 2022 年以来，团队入选报告数量持续攀升，充分展现了团队在血液病与造血干细胞移植领域持续增强的科研产出能力与国际学术影响力。
口头报告（ORAL）
01 第一作者：杨君芳，通讯作者：陆佩华
题目：CD7-targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy Shows Good Efficacy and Safety in Refractory/Relapsed Mixed Phenotype Acute Leukemia (MPAL)
02 第一作者：曹星玉，通讯作者：陆佩华
题目：Long-Term Outcomes of Sequential CD7 CAR-T Therapy and Second Allogeneic Transplantation for T-ALL/LBL Relapsed After a Prior Allo-Transplant
墙报展示（POSTER）
01 第一作者：薛松，通讯作者：曹星玉
题目：Outcomes of Third Allogeneic Hematopoietic Stem Cell Transplantation Among Hematological Malignancy Patients Relapse Post Second Allogeneic Hematopoietic Stem Cell Transplantation
02 第一作者：何洋，通讯作者：曹星玉
题目：Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: A Single-Center Retrospective Analysis of 38 Patients
03 第一作者：刘继聪，通讯作者：曹星玉
题目：A Retrospective Analysis of The Clinical Characteristics, Risk Factors, and Prognosis of Fusarium Infection in Hematologic Patients Before And After Hematopoietic Stem Cell Transplantation
04 第一作者：李璧新，通讯作者：曹星玉
题目：Efficacy and Safety Analysis of PD-1 Inhibitors in Acute Leukemia Patients With Minimal Residual Disease After Allogeneic Haematopoietic Stem Cell Transplantation
05 第一作者：刘婷，通讯作者：曹星玉
题目：Impact of Hepatitis E Virus Infection on Allogeneic Hematopoietic Stem Cell Transplantation And Current Treatment Status
06 第一作者：胥方，通讯作者：卢岳
题目：Efficacy and Safety of Blinatumomab As Combination of Induction or Early Consolidation Therapy In Newly Diagnosed B Cell Acute Leukemia
07 第一作者：孙柏青，通讯作者：卢岳
题目：Excellent Outcome of Allogeneic Hematopoietic Stem Cell Transplantation For Pediatric And Adult Nup98-Rearranged Acute Myeloid Leukemia: A Single Center Real-World Study
08 第一作者：张娜，通讯作者：卢岳
题目：Prognosis Analysis of Allogeneic Hematopoietic Stem Cell Transplantation In The Treatment Of Myeloid Sarcoma: A Single-Center Study
09 第一作者：卢岳，通讯作者：卢岳
题目：Second Allogeneic Hematopoietic Stem Cell Transplantation From Different Donor For Patients With Acute Leukemia Relapsed After First Transplantation：A Single Center Real World Study
10 第一作者：陈曼，通讯作者：王卉
题目：CD72-Gated Pre-CAR-T MRD As A Novel Predictor of Post-Transplant Outcomes In R/R B-ALL Achieving MRD-Negative Remission After CD19 CAR-T Therapy
11 第一作者：王卉，通讯作者：王卉
题目：An Early Myeloid Stem Cells-Based Immunophenotypic Panel Can Rapidly And Efficiently Distinguish APL From APL-Like
12 第一作者：赵玮，通讯作者：陆佩华
题目：Letermovir Prophylaxis Reshapes Early Immune Reconstitution And CMV/EBV Reactivation Dynamics After Allogeneic HSCT
13 第一作者：赵玮/陈曼，通讯作者：陆佩华
题目：Differential Immune Reconstitution Across Age Groups After Allo-HSCT: A Longitudinal Analysis Of Pediatric, Adult, And Elderly Patients
14 第一作者：刘晓红，通讯作者：刘德琰
题目：Gemtuzumab Ozogamicin Enables Bridging To 2nd/3rd Allo-HSCT With Favorable Outcomes In CD33-High Relapsed/Refractory AML With Post–Allo-HSCT Relapse
15 第一作者：潘飞，通讯作者：魏志杰
题目：Long-Term Outcomes of Haploidentical And Matched Unrelated Donor Hematopoietic Stem Cell Transplantation In Complete Remission Non-DS-AMKL: A Single-Center Cohort Study
16 第一作者：潘飞，通讯作者：魏志杰
题目：Determinants of GVHD And Survival After Haploidentical Hematopoietic Stem Cell Transplantation For Acute Myeloid Leukemia: A Single-Center Analysis of 169 Patients
17 第一作者：赵艳丽，通讯作者：陆佩华
题目：Long-Term Outcomes of Haploidentical, Matched Sibling, And Matched Unrelated Donor HSCT In 133 Elderly Patients With Hematologic Malignancies: A Single-Center Comparative Study
18 第一作者：张建平，通讯作者：张建平
题目：High CD34⁺ Cell Dose Significantly Reduces EBV Reactivation and Improves Survival in Aplastic Anemia Patients Undergoing UCBT
电子墙报展示（ePOSTER）
01 第一作者：秦敬媛，通讯作者：陈娟
题目：Risk Factors For Adverse Events During Therapeutic Plasma Exchange In Allo-HSCT Recipients: A Retrospective Cohort Study
02 第一作者：刘晓红，通讯作者：刘德琰
题目：Comparative Outcomes of Three Different ATLG Regimens In Allo-HSCT For Patients With Hematological Malignancies: A Retrospective Study
03 第一作者：杨帆，通讯作者：曹星玉
题目：Prognostic Analysis of Allogeneic Hematopoietic Stem Cell Transplantation with TBI/TMLI and Venetoclax-Based Conditioning for Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
04 第一作者：李楠楠，通讯作者：张建平
题目：Observation of Abatacept + ATG in Prophylaxis CNI Intolerance in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
05 第一作者：朱君利，通讯作者：熊敏
题目：Post-Transplant Antithymocyte Globulin as an Alternative GVHD Prophylaxis Strategy in Haploidentical HSCT: A Feasibility Analysis
06 第一作者：张铭楠，通讯作者：孙瑞娟
题目：Clinical Efficacy of Hematopoietic Stem Cell Transplantation in 20 JMML Cases: A Single-Center Study
07 第一作者：董长伟，通讯作者：张建平
题目：Successful Treatment of Secondary Histiocytic Sarcoma After B-ALL Transplantation With Targeted Therapy Combined With Radiotherapy: A Case Report
作为中国血液病诊疗与细胞治疗领域的重要力量，陆道培医学团队正以更加系统、开放和国际化的姿态，深度参与全球学术对话。未来，团队将继续坚持以临床问题为导向、以科研创新为驱动，推动造血干细胞移植与细胞治疗技术不断突破，为更多血液病患者带来切实可及的治疗新选择。
好文章，需要你的鼓励
